Great posts and enthusiasm narmac and kelsee. I must admit even my cynical little brain is showing a spark of excitment for Zenith.

However, the IND is just what we should have expected as I understand it. Good to have it done and the science seems to be continuing in a steady positive direction. The partneship with Pfizer is a really big deal in terms of credibility and brand profile.

This company has many years of trials to complete before zen3694 (or other drugs) will ever be on the market generating revenue if it ever gets to that stage. If BoM is successful it will be at least 2021/2012 before revenue flows into ZCC.

So from a liquidity or money generating POV for investors based on the plan as laid out in January we've got years to go. Even if ZCC generates income there are no guarantees that there will be any distribution of $. If Don is building a biotech capital company for the long term it would be in the best interest of the company to hold and re-invest earned $ in the company to continue development.

In addition I've sensed for a very long time that Don is not a fan retail investors so the idea of a stock listing as per TSX or NASDAQ (even though he superficially addresses it at AGMs to appease investors like me) is probably really not on the books. However, the big players and Don's friends and family are going to want a payback at some time.

I've been around too long to keep my rose coloured glasses on. Last summer I diluded myself in to thinking that ZEN or ZCC were basically sold based on B & B and notes from the AGM and again I was wrong.

Also, it seems that Don is really struggling more than ever to raise capital.

I am very excited by the science and the fact that Pfizer has been watching RVX and Zenith is now in a type of partnership with Pfizer. This is wonderful progress. Just think about the types of scientific conversations being had on an informal basis.

So...anything can happen and there are a number of triggers.

1. Narmac, as you pointed out a positive BoM I agree will surely have a positive impact on Zenith.
2. Based on articles I read in the Globe in December, BPs are now pointing their guns at filling their pipelines, particularly in cancers. They are looking for high margin compounds.
3. From what I understand zen3694 has demonstrated in pre-clinical trials it has the potential to positively impact more than 25 drugs that are on the market...5 of which are owned by Pfizer. So that there are 20+ owned by other drug companies. Just think of the chess game this could create in terms of deals and buyouts or royalties.
4. If Zenith figures out why and who responds well to zen3694 as per page 17 of the Feb presentation it could represent a breakthrough.
5. zen3694 seems to be achieving an acceptable safety profile in the mCRPC trial (I think?????)

So even though I am guarded I am very positive for the long term (next 5 years) and something could happen in the interim.

GLTA and thanks for sharing all of the incredible insights.

Cheers

Toinv